Letters sent to healthcare professionals in May 2018

Letters were sent about azithromycin, Lynparza▼(Olaparib), Xgeva▼ (denosumab), Lymphoseek (tilmanocept), ReoPro (abciximab) and dolutegravir; you still have time to complete a quick survey to tell us your views on the way medicines safety issues are communicated.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 22 June 2018

• Therapeutic area: Cancer, Cardiovascular disease and lipidology, Haematology, Immunosuppression and transplantation, Infectious disease, Obstetrics, gynaecology and fertility and Radiology and imaging

In May 2018, letters were sent to healthcare professionals about:

• Azithromycin: increased rate of relapses of haematological malignancies and mortality in hematopoietic stem cell transplantation (HSCT) patients treated with azithromycin

• Lynparza▼(Olaparib): Risk of medication errors with new pharmaceutical form

• Xgeva▼ (denosumab): risk of new primary malignancy

• Lymphoseek (tilmanocept) radiopharmaceutical preparation: temporary extension of shelf life of lot F03016002

• ReoPro (abciximab) 2 mg/mL solution for injection or infusion: Indefinite Supply Shortage

• Tivicay▼ (dolutegravir), Triumeq▼ (dolutegravir, abacavir, lamivudine), Juluca▼ (dolutegravir, rilpivirine): neural tube defects reported in infants born to women exposed to dolutegravir at the time of conception

You still have time to complete this 10-minute survey to tell us your views on the way medicines safety issues are communicated and how we might improve this to better support safe and effective use.

Article citation: Drug Safety Update volume 11, issue 11; June 2018: 4.

Published 22 June 2018